Solana Company reports developments as a Nasdaq-listed company with a digital asset treasury dedicated to acquiring and holding Solana tokens (SOL) and a legacy neurotechnology medical-device business. News commonly covers SOL accumulation, staking rewards, NAV-per-share capital strategy, ATM and registered-direct equity financing, share repurchases, and financial results shaped by digital-asset fair value changes.
Company updates also describe institutional Solana infrastructure initiatives in Asia-Pacific, including validator and staking infrastructure, qualified-custody borrowing against natively staked SOL, and ecosystem partnerships with organizations such as Jito Foundation, Anchorage Digital, and Kamino.
Helius Medical Technologies (Nasdaq:HSDT) launched a Patient Therapy Access Program (PTAP) to improve access to its Portable Neuromodulation Stimulator (PoNS) Therapy for patients with multiple sclerosis (MS). This initiative offers eligible patients reduced pricing for PoNS, which is prescribed for gait deficits due to mild-to-moderate MS symptoms. The program aims to drive adoption of PoNS Therapy and supports data collection for future clinical evidence. PTAP will run until December 31, 2022, enhancing access for first-time users of the therapy.
Helius Medical Technologies (Nasdaq: HSDT) announced a poster presentation at the Consortium for Multiple Sclerosis Centers (CMSC) Annual Meeting from June 1-4, 2022. The highlighted abstract showcases real-world data indicating that translingual neurostimulation can effectively improve gait in multiple sclerosis patients. Chief Medical Officer Antonella Favit-Van Pelt emphasized the benefits of neuromodulation in enhancing walking stability and promoting neuroplasticity. The presentation is scheduled for June 2 at 5:00 p.m. ET, with Helius representatives available to discuss the Portable Neuromodulation Stimulator (PoNS) device at Booth #804.
Helius Medical Technologies (HSDT) announced that its independent directors have approved the issuance of equity awards as part of its 2021 Inducement Plan, effective May 23, 2022. Four new employees, not previously associated with Helius, received options to purchase a total of 21,000 shares at an exercise price of $1.40 each, which reflects the closing stock price on the date of the grant. These options will vest over four years, providing Helius with a strategic advantage in attracting talent while adhering to Nasdaq regulations.
Helius Medical Technologies has expanded its Therapeutic Experience Program (TEP) by adding Shepherd Center in Atlanta as a second Center of Excellence. This multi-center observational trial aims to assess the effectiveness of Portable Neuromodulation Stimulator (PoNS) therapy for gait improvement in patients with multiple sclerosis (MS). Led by Dr. Deborah Backus, the program will provide valuable data on treatment adherence and outcomes, with enrollment expected to begin in Q2 2022.
Helius Medical Technologies (HSDT) reported a 126% increase in Q1 2022 revenue to $190,000, up from $84,000 in Q1 2021. The U.S. commercial launch of PoNS for multiple sclerosis began, with 23 prescriptions written. Operating loss widened to $4.6 million compared to $3.5 million in Q1 2021. Cash used in operations rose to $4.7 million from $2.9 million. The company anticipates being cash flow positive by Q4 2023, projecting sequential revenue growth beyond the first quarter.
Helius Medical Technologies (NASDAQ: HSDT) will release its Q1 2022 financial results on May 12, 2022, before market opening. CEO Dane C. Andreeff and CFO Jeffrey S. Mathiesen will lead a conference call to discuss the results and provide insights into Helius' plans for the U.S. commercialization of PoNS®, its first medical device aimed at improving neurological wellness. The call is scheduled for 9:00 a.m. ET, with details available via the webcast.
Helius Medical Technologies (HSDT) announced the fulfillment of the first prescriptions for its Portable Neuromodulation Stimulator (PoNS) therapy aimed at treating gait deficits in multiple sclerosis (MS) patients. Following its commercial launch in the U.S., there have been 19 PoNS prescriptions written, with two patients commencing therapy. The device, previously available in Canada, is marketed on a cash pay basis as the company seeks reimbursement from insurers. This launch marks a significant step in addressing the needs of nearly one million MS patients in the U.S.
Helius Medical Technologies (Nasdaq: HSDT) has launched its Portable Neuromodulation Stimulator (PoNS®) in the U.S. to assist Multiple Sclerosis (MS) patients with gait deficits. Approved by the FDA, PoNS is a non-surgical device designed for individuals aged 22 and over, complementing physical therapy. Approximately 70% of the one million MS patients in the U.S. experience gait-related mobility issues. Helius aims to enhance patient mobility through innovative neuromodulation therapy. The company is also advancing research partnerships to further validate PoNS Therapy effectiveness.
Helius Medical Technologies (HSDT) reported a 35% increase in Q4 2021 revenue, reaching $258,000, compared to $191,000 in Q4 2020. However, total revenue for the full year decreased to $522,000 from $661,000 in 2020. Operating expenses rose to $4.2 million, leading to an operating loss of $4.1 million in Q4. The company closed a public offering with $11.1 million in gross proceeds and is preparing for the U.S. commercial launch of PoNS for multiple sclerosis. Guidance for Q1 2022 projects revenue of $150,000 to $170,000.
Helius Medical Technologies (HSDT) announced the approval of equity awards to two new employees as part of its 2021 Inducement Plan, effective February 16, 2022. This follows Nasdaq Listing Rule 5635(c)(4), requiring public announcements for non-stockholder approved equity awards. The new hires received options to purchase a total of 2,000 shares at $4.68 each, valid for ten years, with a four-year vesting period. Helius specializes in neurotech solutions and is focused on improving neurologic conditions through its innovative PoNS device.